Antidepressant medication % members 18 years of age or younger diagnosed with a new episode of NCQA/HEDIS/AHRQ A management, continuation phase depression and treated with antidepressant medication, who remained on an antidepressant for at least 180 days Optimal medication provider % of members 18 years of age or younger with a new episodes of NCQA/HEDIS/AHRQ C contacts, acute phase depression with 3 or more medication visits by a prescribing provider (e.g., physician or nurse practitioner) in the 84-day (12 week) acute treatment phase Optimal psychotherapy provider % of members 18 years of age or younger with a new episodes of NCQA/HEDIS/AHRQ C contacts, acute phase depression with 6 or more outpatient mental health visits in the 84-day (12 week) acute treatment phase Adequacy of antidepressant dosage % of members 18 years of age or younger with new episodes of APA/AHRQ A depression and treated with antidepressants, who received an appropriate dose (e.g., within the recommended therapeutic range) Bipolar Disorder Use of appropriate medication % of enrollees 18 years of age or younger who receive either a mood CQAIMH/STABLE/ A stabilizer and/or antipsychotic within 84-days (12 weeks) of the initial AACAP/APA bipolar diagnosis Blood levels for mood stabilizers % of enrollees 18 years of age or younger with 1 serum medication CQAIMH/STABLE/ B ≥ blood level test within 84-days (12 weeks) of initiation of lithium or Research mood stabilizer (carbamazepine, divalproex sodium/valproic acid) Side effect monitoring of mood % of enrollees 18 years of age or younger with 1 thyroid or renal AACAP B ≥ stabilizers function test within 84-days (12 weeks) after initiation of lithium or 1 ≥ liver test within 84-days (12 weeks) after initiation of valproic acid or carbamazepine Metabolic screening when an % of enrollees 18 years of age or younger with 1 plasma glucose test CQAIMH/STABLE A ≥ antipsychotic is prescribed and 1 lipids test within 112-days (16 weeks) after initiating an atypical ≥ antipsychotic
Antidepressant medication management, continuation phase Optimal medication provider contacts, acute phase Optimal psychotherapy provider contacts, acute phase Adequacy of antidepressant dosage % members 18 years of age or younger diagnosed with a new episode of depression and treated with antidepressant medication, who remained on an antidepressant for at least 180 days % of members 18 years of age or younger with a new episodes of depression with 3 or more medication visits by a prescribing provider (e.g., physician or nurse practitioner) in the 84-day (12 week) acute treatment phase % of members 18 years of age or younger with a new episodes of depression with 6 or more outpatient mental health visits in the 84-day (12 week) acute treatment phase % of members 18 years of age or younger with new episodes of depression and treated with antidepressants, who received an appropriate dose (e.g., within the recommended therapeutic range) NCQA/HEDIS/AHRQ NCQA/HEDIS/AHRQ NCQA/HEDIS/AHRQ APA/AHRQ A C C A Bipolar Disorder Use of appropriate medication Blood levels for mood stabilizers Side effect monitoring of mood stabilizers Metabolic screening when an antipsychotic is prescribed % of enrollees 18 years of age or younger who receive either a mood stabilizer and/or antipsychotic within 84-days (12 weeks) of the initial bipolar diagnosis % of enrollees 18 years of age or younger with ≥ 1 serum medication blood level test within 84-days (12 weeks) of initiation of lithium or mood stabilizer (carbamazepine, divalproex sodium/valproic acid) % of enrollees 18 years of age or younger with ≥ 1 thyroid or renal function test within 84-days (12 weeks) after initiation of lithium or ≥ 1 liver test within 84-days (12 weeks) after initiation of valproic acid or carbamazepine % of enrollees 18 years of age or younger with ≥ 1 plasma glucose test and ≥ 1 lipids test within 112-days (16 weeks) after initiating an atypical antipsychotic CQAIMH/STABLE/ AACAP/APA CQAIMH/STABLE/ Research AACAP CQAIMH/STABLE A B B A
QualityMeasures.docx